Because the low immunogenicity of tumor cells is one of the mechanisms that tumors use to escape from the immune surveillance, one of immunotherapeutic strategies aims at enhancing the presentation of tumor antigens to T cells. This makes therapeutic cancer vaccines an attractive alternative, in which adjuvants are necessary to facilitate the induction and achievement of the desired immune response to weak antigens.
In this respect, Explicyte is offering an immunization model based on the co-administration of adjuvants poly(I:C) (TLR3 ligand) and agonistic anti-CD40 antibody into tumor-bearing mice, and adapted for the evaluation of drug candidate for their ability to boost the anti-tumor immunity.
TLR3 ligation-CD40 activation immunization model
- Syngeneic tumor models – tumor cells are inoculated into immunocompetent mice to keep intact the host immune response against the tumor.
- A validated treatment protocol in line with published literature data.
- An adapted therapeutic window to evaluate potential synergistic effects with drug candidate.